PD-L2/CD273 Polyclonal antibody

PD-L2/CD273 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, ELISA

Conjugate

Unconjugated

Publications

16

Cat no : 18251-1-AP

Synonyms

B7 DC, Btdc, Butyrophilin B7 DC, CD273, PD 1 ligand 2, PDCD1 ligand 2, PDCD1L2, PDCD1LG2, PDL2, PD-L2, PD-L2/CD273, Programmed death ligand 2

---

Validation Data Gallery

• 

  WB analysis using 18251-1-AP

  NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 18251-1-AP (PD-L2/CD273 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of RAW 264.7 using 18251-1-AP

  RAW 264.7 cells were subjected to SDS PAGE followed by western blot with 18251-1-AP (PD-L2/CD273 antibody at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse heart using 18251-1-AP

  mouse heart tissue were subjected to SDS PAGE followed by western blot with 18251-1-AP (PD-L2/CD273 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HepG2 using 18251-1-AP

  HepG2 cells were subjected to SDS PAGE followed by western blot with 18251-1-AP (PD-L2/CD273 antibody at dilution of 1:300 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: NIH/3T3 cells, mouse heart tissue, HepG2 cells, RAW 264.7 cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Published Applications

• WB: See 5 publications below
• IHC: See 13 publications below

Product Information

18251-1-AP targets PD-L2/CD273 in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.

• Tested Reactivity: human, mouse, rat
• Cited Reactivity: human, mouse
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: PD-L2/CD273 fusion protein Ag13039
• Full Name: programmed cell death 1 ligand 2
• Calculated Molecular Weight: 273 aa, 31 kDa
• Observed Molecular Weight: 40-50 kDa, 28 kDa
• GenBank Accession Number: BC074766
• Gene Symbol: PD-L2
• Gene ID (NCBI): 80380
• RRID: AB_2878523
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Programmed cell death ligand 2 (PD-L2, also known as CD273, or B7-DC), is one of the B7 family molecules which are type I transmembrane proteins belonging to the immunoglobulin superfamily. PD-L2 was identified both by its homology to PD-L1 and by analysis of genes differentially expressed in libraries generated from dendritic cells (DC) and activated macrophages (PMID: 14515254). PD-L2 is a second ligand for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery.

Publications

Species	Application	Title
human	WB,IHC	Aging Cell; Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.; Authors - Qixia Xu
human	WB	J Nutr Biochem; Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression; Authors - Qi Zhang
human	IHC	Cancer Sci; ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.; Authors - Keita Katsurahara
human	IHC	J Cell Mol Med; IFI30 expression is an independent unfavourable prognostic factor in glioma.; Authors - Xiu Liu
human	WB	J Transl Med; Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.; Authors - Zhao-Ying Yang
human	IHC	Oncol Rep; Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.; Authors - Ryota Sumitomo